Literature DB >> 21862310

Strategies for extended serum half-life of protein therapeutics.

Roland E Kontermann1.   

Abstract

With a growing number of protein therapeutics being developed, many of them exhibiting a short plasma half-life, half-life extension strategies find increasing attention by the biotech and pharmaceutical industry. Extension of the half-life can help to reduce the number of applications and to lower doses, thus are beneficial for therapeutic but also economic reasons. Here, a comprehensive overview of currently developed half-life extension strategies is provided including those aiming at increasing the hydrodynamic volume of a protein drug but also those implementing recycling processes mediated by the neonatal Fc receptor.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21862310     DOI: 10.1016/j.copbio.2011.06.012

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  147 in total

1.  Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains.

Authors:  Meike Hutt; Aline Färber-Schwarz; Felix Unverdorben; Fabian Richter; Roland E Kontermann
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

Review 2.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

3.  In vitro selection of a peptide antagonist of growth hormone secretagogue receptor using cDNA display.

Authors:  Shingo Ueno; Sayaka Yoshida; Anupom Mondal; Kazuya Nishina; Makoto Koyama; Ichiro Sakata; Kenju Miura; Yujiro Hayashi; Naoto Nemoto; Koichi Nishigaki; Takafumi Sakai
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

4.  Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.

Authors:  Felix Unverdorben; Fabian Richter; Meike Hutt; Oliver Seifert; Pauline Malinge; Nicolas Fischer; Roland E Kontermann
Journal:  MAbs       Date:  2016       Impact factor: 5.857

Review 5.  Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Authors:  Yingzhi Chen; Meng Zhang; Kyoung Ah Min; Huiyuan Wang; Meong Cheol Shin; Feng Li; Victor C Yang; Yongzhuo Huang
Journal:  Curr Drug Targets       Date:  2018-02-19       Impact factor: 3.465

6.  Palladium(II)-Catalyzed Site-Selective C(sp3 )-H Alkynylation of Oligopeptides: A Linchpin Approach for Oligopeptide-Drug Conjugation.

Authors:  Tao Liu; Jennifer X Qiao; Michael A Poss; Jin-Quan Yu
Journal:  Angew Chem Int Ed Engl       Date:  2017-08-07       Impact factor: 15.336

7.  Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.

Authors:  Zeliang Zheng; Ryuhei Okada; Hisataka Kobayashi; Tadanobu Nagaya; Junxia Wei; Qi Zhou; Fred Lee; Tapan K Bera; Yun Gao; William Kuhlman; Chin-Hsien Tai; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2019-12-23       Impact factor: 6.261

8.  Zwitterionic Hydrogels Based on a Degradable Disulfide Carboxybetaine Cross-Linker.

Authors:  Priyesh Jain; Hsiang-Chieh Hung; Bowen Li; Jinrong Ma; Dianyu Dong; Xiaojie Lin; Andrew Sinclair; Peng Zhang; Mary Beth O'Kelly; Liqian Niu; Shaoyi Jiang
Journal:  Langmuir       Date:  2018-08-30       Impact factor: 3.882

9.  Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain.

Authors:  Mischa R Müller; Kenneth Saunders; Christopher Grace; Macy Jin; Nicole Piche-Nicholas; John Steven; Ronan O'Dwyer; Leeying Wu; Lam Khetemenee; Yulia Vugmeyster; Timothy P Hickling; Lioudmila Tchistiakova; Stephane Olland; Davinder Gill; Allan Jensen; Caroline J Barelle
Journal:  MAbs       Date:  2012 Nov-Dec       Impact factor: 5.857

Review 10.  Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.

Authors:  Pedro P G Guimarães; Stephanie Gaglione; Tomasz Sewastianik; Ruben D Carrasco; Robert Langer; Michael J Mitchell
Journal:  ACS Nano       Date:  2018-02-06       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.